Orforglipron (Foundayo) Explained: A Complete Guide to the New Mounjaro Pill

Weight loss treatments have changed quickly in recent years, with injections like Mounjaro and Wegovy becoming more widely used. Now, a new option is starting to gain attention. Orforglipron (pronounced or-FOR-gli-pron) is a daily GLP-1 tablet developed by Eli Lilly, offering a different way to approach treatment.

In the US, it’s available under the brand name Foundayo for weight management. You may also see it referred to as the “Mounjaro pill” because it comes from the same manufacturer, although it works slightly differently. It’s not yet approved in the UK and is currently under review by the Medicines and Healthcare products Regulatory Agency (MHRA).

In this guide, you’ll find a clear explanation of what orforglipron is, how it works, and how effective it appears to be. We’ll also cover when it may become available in the UK, possible side effects, and how it compares with treatments like Mounjaro injections, Wegovy injections and the Wegovy pill.

Orforglipron At A Glance

• Approved by the Food and Drug Administration (FDA) and sold as Foundayo in the US¹
• Taken as a tablet instead of a weekly injection
• Not yet available in the UK
• Expected UK launch between 2026 and 2027
• Works by reducing appetite and increasing fullness
• Still under regulatory review in the UK
• Up to 11.2% average weight loss in clinical trials at the highest dose over 72 weeks²

What Is Orforglipron (Foundayo)?

If you’ve been looking into weight loss treatments, you may have come across injections like Wegovy or Mounjaro. While they can be effective, not everyone feels comfortable using a pen device, which is where newer options are starting to differ.

Orforglipron (Foundayo), is an oral GLP-1 receptor agonist, meaning it belongs to the same group of medicines as semaglutide and tirzepatide, but instead of being injected, it’s taken as a tablet.

GLP-1 medicines mimic a natural hormone produced in your body that helps regulate appetite and blood sugar levels. In simple terms, they help you feel fuller for longer and reduce how much you eat.²

For many people, the biggest appeal is simple. Orforglipron is a tablet, not an injection. This means it could offer a more convenient option if you want the appetite and weight loss support associated with GLP-1 treatments, but would prefer not to use a pen device.

Is Orforglipron the Same as Mounjaro?

It’s easy to assume they are the same, especially since both are made by Eli Lilly.

However, they are different treatments.

Mounjaro contains tirzepatide and works on two hormones involved in appetite and blood sugar control, GLP-1 and GIP. Orforglipron works on GLP-1 receptors only.

Because Mounjaro targets two pathways, it has shown higher average weight loss in clinical trials. Orforglipron, while working on a single pathway, still delivers meaningful weight loss and may offer a simpler option as a once-daily tablet rather than an injection.

When Will Orforglipron Be Available in the UK?

Orforglipron is not yet available in the UK.

In the US, it was approved in April 2026 under the brand name Foundayo and became available shortly after. In the UK, it’s still under review by the MHRA.

While an exact date has not been confirmed, it’s expected that orforglipron could become available in the UK between 2026 and 2027, depending on regulatory approval and rollout timelines.

Before it becomes available, it must go through strict safety and effectiveness checks.

*These timelines are based on current information and industry expectations. UK approval and availability have not yet been confirmed and may change depending on regulatory review.

Where Can I Buy Orforglipron In The UK?

For now, access to orforglipron in the UK will only be possible once it has been approved and prescribed through regulated healthcare providers such as The Independent Pharmacy.

This matters because treatments like this should always be supplied through trusted, regulated channels. It ensures the medication is genuine, the dose is correct and that you’re being properly assessed before starting.

When it does become available, it’s likely to:

• Be offered through private prescriptions first
• Be supplied by regulated UK pharmacies
• Require a medical consultation before treatment

This structure is there to protect you, making sure the treatment is both safe and appropriate for your needs.

In the meantime, there are already proven, regulated options available, including Mounjaro injections and Wegovy injections, which can be accessed through a simple online consultation. You can also explore the best weight loss injection options in the UK to compare what’s currently available.

Can You Order Foundayo From the US and Have It Shipped to the UK?

No, you cannot order Foundayo (orforglipron) from the US and have it shipped to the UK, even if it’s supplied by the manufacturer.

Although Foundayo is available in the US, it has not yet been approved by the MHRA. Because of this, it cannot be legally prescribed or supplied in the UK.

Prescription-only medicines are regulated differently in each country, and treatments approved in the US are not automatically approved for use in the UK. This means manufacturers such as Eli Lilly do not ship prescription medicines directly to UK patients.

It’s also not recommended to try to import medication from overseas websites, as you cannot always be sure the treatment is genuine, stored correctly or appropriate for you.

For your safety, weight loss treatments should always be accessed through regulated UK providers following a consultation.

Once Foundayo is approved in the UK, it’s expected to be available through prescription in the same way as other GLP-1 treatments.

How Much Does Orforglipron Cost?

Pricing has not yet been confirmed in the UK.

In the US, where orforglipron is sold as Foundayo, the cost varies depending on insurance and dosage. Some patients may pay as little as around $25 per month with insurance and savings programmes. Without insurance, prices typically start from around $149 per month and can rise to approximately $300 or more depending on the dose.⁶

UK pricing will be confirmed if and when the treatment is approved.

Orforglipron NHS Eligibility

Even if orforglipron is approved for use in the UK, it would not automatically be available on the NHS straight away.

Before any new medicine can be prescribed in the NHS, it must go through two key stages. First, it needs to be licensed by the MHRA, which assesses whether it is safe, effective and of good quality. After this, it must be reviewed by the National Institute for Health and Care Excellence (NICE), which looks at both how well the treatment works and whether it provides value for money for the NHS.

Only if NICE recommends it would orforglipron be routinely available on the NHS.

If it’s approved, eligibility is likely to follow current GLP-1 prescribing criteria. This may include:

• A BMI of 30 or above
• A BMI of 27 or above with weight-related health conditions

Even with approval, access may be limited at first and prioritised for patients who meet strict clinical criteria.

In England, once a treatment is recommended by NICE, it’s usually made available within three months. However, timelines can vary across the UK depending on local health systems.

NHS approval timelines across the UK

Source: Deciding which medicines are used in the NHS 

How Does Orforglipron Work?

At a technical level, orforglipron works by activating something called the GLP-1 receptor.

GLP-1 (glucagon-like peptide-1) is a natural hormone your body releases after you eat. Its job is to help regulate appetite, digestion and blood sugar levels.

Orforglipron mimics this hormone by binding to GLP-1 receptors in the body, which triggers several effects:

1. It reduces appetite

One of the main effects happens in the brain.

Orforglipron signals to appetite centres in the brain that you’ve had enough to eat, helping reduce hunger and food cravings.

2. It slows stomach emptying

It also slows how quickly food leaves your stomach.

This means you feel full for longer after eating, which can naturally reduce how much you eat throughout the day.

3. It helps regulate blood sugar

Orforglipron increases insulin release when blood sugar levels are high and reduces the amount of glucose released by the liver.

This helps keep blood sugar levels more stable, which can also reduce hunger spikes.

4. It supports long-term weight loss

By combining these effects, reduced appetite, longer fullness, and more stable blood sugar, it helps create a consistent calorie deficit over time.

So what makes orforglipron different?

Most GLP-1 treatments (like semaglutide) are peptide-based and need to be injected.

Orforglipron is a non-peptide GLP-1 receptor agonist, which means it can be taken as a tablet while still activating the same biological pathway.

In simple terms

Orforglipron works with your body’s natural hunger signals to help you:

• Feel less hungry
• Feel full for longer
• Eat less without needing to rely on willpower alone

How Do You Take Orforglipron?

Orforglipron is taken as a once-daily tablet, which makes it different from injectable treatments that are usually taken weekly.

It’s designed to be simple to fit into your routine, but it’s important to take it exactly as prescribed.

Key points:

• Taken once per day by mouth
• Can be taken with or without food
• Swallowed whole with water (not crushed, broken or chewed)
• Used alongside a reduced-calorie diet and increased physical activity
• Should be taken exactly as your healthcare provider advises

If you miss a dose, take it as soon as possible, but do not take more than one tablet in a day. For full guidance, refer to the patient information leaflet.

It’s important to note that with orforglipron there are no food or water timing restrictions, so it can be taken at any time of day.

How Effective Is Orforglipron?

In phase 3 clinical trials, orforglipron has shown meaningful weight loss when used alongside diet and exercise.

In the ATTAIN-1 trial, which included over 3,000 adults with obesity without diabetes, people taking the highest dose lost an average of 11.2% of their body weight over 72 weeks, compared with 2.1% with placebo.²

Lower doses also produced consistent results, with weight loss of around 7% to 8%, while those using diet and exercise alone lost around 2% on average.

In a separate phase 3 study (ATTAIN-2) involving adults with type 2 diabetes, average weight loss ranged from around 5.1% to 9.6%, compared with around 2.5% with placebo.⁴

Across the clinical programme, this equates to roughly 2 to 5 times greater weight loss compared with diet and exercise alone, depending on the dose and patient group.³

Who Is Orforglipron Suitable For?

If approved, orforglipron may be suitable for adults who:

• Have a BMI of 30 or above
• Have a BMI of 27 or above with related health conditions

It may be a good option if you:

• Prefer tablets over injections
• Feel uncomfortable with needles
• Want a more flexible treatment format

A prescriber would always need to assess your suitability.

What Is The Difference Between Orforglipron Tablets And Mounjaro Injections?

Is Orforglipron As Effective As Mounjaro Injections?

In clinical trials, orforglipron has shown meaningful weight loss when used alongside diet and lifestyle changes.

In a phase 2 trial published in the New England Journal of Medicine, adults with obesity or overweight without diabetes lost up to 14.7% of their body weight over 36 weeks, compared with around 2.3% with placebo.²

In a separate phase 2 study in adults with type 2 diabetes, average weight loss was up to around 10.1 kg at 26 weeks, significantly greater than placebo.⁴

More recent phase 3 trial data have reported weight loss of up to 11.2% over 72 weeks in adults with obesity without diabetes, with lower doses producing consistent but more modest results.³

Can I Switch From Mounjaro Injections to Orforglipron?

Potentially, yes.

However, you should not switch treatments without medical advice. Even though both medicines affect appetite in similar ways, they work slightly differently and are taken in different formats.

Your dose, timing and how your body responds all need to be considered carefully.

Switching too quickly or without guidance could increase your risk of side effects or reduce how effective the treatment is.

A prescriber would guide the transition, making sure the change is safe, well-timed and tailored to you.

As more tablet options become available, switching between treatments may become more common, but it should always be done with professional support.

Possible Side Effects of Orforglipron (Foundayo)

Like other GLP-1 treatments, orforglipron can cause side effects, especially when you first start or increase your dose.

The most common ones are linked to how the medication works in your digestive system, and may include:

• Nausea
• Diarrhoea
• Vomiting
• Constipation
• Stomach discomfort

For most people, these side effects are mild and tend to improve as your body adjusts to the treatment.

If symptoms do occur, there are ways to manage them, including simple dietary changes and supportive treatments that can help ease nausea, reflux and digestive discomfort.

As these effects are similar across GLP-1 treatments, our guide on how to manage common side effects of Wegovy includes practical tips that may also help, particularly if you’re currently using Wegovy or considering similar treatments.

Serious side effects are rare, but it’s important to seek medical advice if anything feels severe, persistent or unusual. It can also be helpful to have side effect treatments on hand to manage common symptoms like nausea, reflux or digestive discomfort.

Orforglipron Alternatives

While waiting for orforglipron, there are effective treatments available now.

These include:

• Mounjaro injections
• Wegovy injections – you can also read about the newest 7.2mg dose here
• Wegovy pill (coming soon) – you can read more about here
• Orlistat capsules

You can explore all available weight loss treatments to find what works best for you.

If you’re considering Wegovy as an alternative, you can also read what the first month on Wegovy is like before getting started.

FAQs

How do I store orforglipron?

You can store orforglipron at room temperature, away from heat and moisture. It’s best to keep it in its original packaging and out of reach of children. If you’re ever unsure, just check the leaflet that comes with your medication.

What orforglipron dosages and strengths are available?

The exact doses for the UK haven’t been confirmed just yet, but we do have a good idea of what to expect based on what’s currently available in the US.

At the moment, orforglipron (Foundayo) is available in the following strengths:

• 0.8mg
• 2.5mg
• 5.5mg
• 9mg
• 14.5mg
• 17.2mg

These different doses allow treatment to be started at a lower level and gradually increased over time, helping your body adjust and reducing the chance of side effects.

How do I switch from Mounjaro Injections to orforglipron?

Switching treatments should always be done with medical guidance.

Your prescriber will advise you on when to stop your injections and how to safely start the tablet, so the transition is smooth and well-timed. This is important because both treatments affect appetite and blood sugar, and switching incorrectly could increase side effects or reduce how well the treatment works.

You should not take both treatments at the same time unless specifically advised by a healthcare professional.

What happens if I miss a dose of orforglipron?

If you miss a dose, take it as soon as you remember.

If it’s close to your next scheduled dose, skip the missed dose and continue as normal. You should not take two doses on the same day.

If you miss several doses in a row (7 days or more), speak to your healthcare provider before restarting treatment.

What happens if you take too much orforglipron?

Taking more than prescribed can increase your chances of side effects like nausea or vomiting. If this happens, it’s best to get medical advice as soon as you can, just to be safe.

What should I avoid while using orforglipron?

There aren’t strict “don’ts”, but a few small tweaks can make a big difference.

Heavier or high-fat meals can sometimes make side effects like nausea or reflux more noticeable, especially early on. Alcohol can have a similar effect for some people.

Keeping meals balanced, staying hydrated and easing into treatment can help your body adjust more comfortably.

What other medicines will affect orforglipron?

Orforglipron can interact with some medicines, so it’s important your prescriber knows everything you’re taking, including over-the-counter treatments and supplements.

This helps make sure everything works safely together. For example, some diabetes medications may increase the risk of low blood sugar when used alongside GLP-1 treatments.

Conclusion

Weight loss treatments have already made a meaningful difference for many people worldwide, and the medical field continues to evolve, developing new options that aim to be more convenient and suitable for those who may benefit from treatment.

Orforglipron represents a newer option in the development of weight loss treatments. As a once-daily tablet that works in a similar way to GLP-1 injections, it may offer an alternative for people who would prefer not to use injections.

While it isn’t available in the UK just yet, the clinical data so far is encouraging. In the meantime, established treatments such as Mounjaro and Wegovy are already available. If you’re deciding between these options, you can read our guide on Mounjaro vs Wegovy for weight loss to understand the key differences.

If appropriate, these can be accessed following a quick and confidential online consultation, with guidance from UK-registered clinicians.

If you’re still exploring your options or would like more information, you can also speak to a UK-registered pharmacist for advice tailored to your needs.

References

1. Eli Lilly and Company. Foundayo (orforglipron) prescribing information and product details. Available at: https://foundayo.lilly.com/
2. Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389:877-888. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2302392
3. Eli Lilly and Company. Orforglipron demonstrated statistically significant weight loss in phase 3 trials (ATTAIN programme). Available at: https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically
4. The Lancet. Oral GLP-1 receptor agonist orforglipron clinical trial data. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01302-8/abstract
5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
6. Eli Lilly and Company. Foundayo pricing and access information. Available at: https://foundayo.lilly.com/

Sources

UK Parliament. Obesity statistics. London: House of Commons Library; 2024. Available from: https://researchbriefings.files.parliament.uk/documents/CBP-10326/CBP-10326.pdf

Electronic Medicines Compendium. Wegovy 0.25mg solution for injection in pre-filled pen – patient information leaflet. Available at: https://www.medicines.org.uk/emc/product/13799/pil

National Center for Biotechnology Information. Orforglipron: a novel oral GLP-1 receptor agonist for weight management. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12898445/

Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 oral pill for weight management. Available at: https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill